the method developed donate a new platform for peptides, ODN and peptide-ODN conjugate synthesis. It allow the formation of linear (dyad and alternate mode) branched and cyclic forms under moderate conditions and can be carried out manually or on...

the method developed donate a new platform for peptides, ODN and peptide-ODN conjugate synthesis. It allow the formation of linear (dyad and alternate mode) branched and cyclic forms under moderate conditions and can be carried out manually or on automatic synthesizer. Keywords: nucleic acids, chemical synthesis

Novel Gene Inhibitors show Efficacy in Anticancer and Anti-Viral Therapy

Category	Cancer, Inflammatory Disease
Development Stage	In vivo proof of concept
Patent Status	Patent Pending
Market Size	73,674 women in the USA are expected to have ovarian cancer at the year 2010; 22,871 in Germany and 22,053 in Japan, the highest prevalence figures in 2010. More than 1.2 million women have been diagnosed with breast cancer in 2005 worldwide, with over 366,000 deaths of breast cancer.

Highlights

• The new drug entities will possess significantly improved pharmacokinetics, manifested by high-performance targeted delivery of drugs across the cellular membrane, enhanced stability and solubility of the active ingredient.
• Development of the systems building blocks and supportive monomers that enhance building blocks binding were achieved, and Blood Brain Barrier (BBB) penetration established in mice.
• Applications include cancers involving genetic mutation of the cell, including breast and ovarian cancer. Other future applications include viral disease such as HIV, Herpes and Polio.

Our Innovation

• A platform for the development of new generation anti-sense peptide nucleic acid (PNA) drugs
• The invention provides molecules comprising  nucleic bases linked to a peptide ligand (polyamide), which binds to a specific DNA strand
• Like anti-sense drugs, PNA drugs are based on gene-silencing, by unregulation of RNA via down-regulation of protein translation.
• Fluorescent materials showed significantly higher penetration of the BBB in mice.

Development Milestones

• Small animal studies will be conducted to test efficacy in ovarian and breast cancers.
• Additional development will target enhancement of the oligomers synthesis.
• Building blocks will be up-scaled, and hybridization mechanism will be improved.

The Opportunity

• The proposed technologys primary target market will be non-responding cancer patients. According to the US National Institute of Cancer, it is estimated that 50% of cancer patients develop multidrug resistance to anticancer drugs.

project-id 12-2006-671

Patent Pending